Navigation Links
Artificial Tanning Causes Concern

te your own shade.
· Slip on light, loose-fitting clothing to cover your arms and legs.
· Slap on a wide-brimmed hat that covers your head, face, ears and neck. Hats without a wide brim, such as baseball caps, do not give enough protection.
· Wear sunglasses, which can help prevent damage to your eyes by blocking a large amount of ultraviolet rays. Choose sunglasses with even shading, medium to dark lenses and UVA and UVB protection.
· Wear sunscreen with an SPF of 15 or higher. If you work outdoors, or if you will be outside for most of the day, use an SPF of 30. Apply sunscreen at least 20 minutes before heading out and reapply every two hours, more often if you’re swimming or sweating.
· Keep babies under one year out of the direct sun.

Source-Medinda
BIN/V
'"/>




Page: 1 2

Related medicine news :

1. Fifth US Patient Receives Artificial Heart
2. First Artificial Heart patient has Major setback
3. Artificial lenses- Boon to cataract patients
4. Artificial silicon retina
5. Artificial disc looks hopeful
6. Artificial discs available as replacements for damaged discs
7. Artificially made protein to inhibit angiogenesis
8. Artificial Heart , Gives Hope For Patients Awaiting a Heart Transplant
9. Artificial Sweetners Not Really Safe?
10. Aspartame, Artificial Sweetener, A Safe Bet!
11. Artificial Light Stimulates Breast Cancer Growth In Mice: Study
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Artificial Tanning Causes Concern

Other Medicine News:Health News:Secretary Shinseki Announces $215 Million in Projects for Rural Veterans 2Health News:FDA Approves SAMSCA(TM) (tolvaptan), the First and Only Oral Vasopressin Antagonist to Treat Patients With Clinically Significant Hypervolemic and Euvolemic Hyponatremia 2Health News:FDA Approves SAMSCA(TM) (tolvaptan), the First and Only Oral Vasopressin Antagonist to Treat Patients With Clinically Significant Hypervolemic and Euvolemic Hyponatremia 3Health News:FDA Approves SAMSCA(TM) (tolvaptan), the First and Only Oral Vasopressin Antagonist to Treat Patients With Clinically Significant Hypervolemic and Euvolemic Hyponatremia 4Health News:FDA Approves SAMSCA(TM) (tolvaptan), the First and Only Oral Vasopressin Antagonist to Treat Patients With Clinically Significant Hypervolemic and Euvolemic Hyponatremia 5Health News:FDA Approves SAMSCA(TM) (tolvaptan), the First and Only Oral Vasopressin Antagonist to Treat Patients With Clinically Significant Hypervolemic and Euvolemic Hyponatremia 6Health News:FDA Approves SAMSCA(TM) (tolvaptan), the First and Only Oral Vasopressin Antagonist to Treat Patients With Clinically Significant Hypervolemic and Euvolemic Hyponatremia 7Health News:FDA Approves SAMSCA(TM) (tolvaptan), the First and Only Oral Vasopressin Antagonist to Treat Patients With Clinically Significant Hypervolemic and Euvolemic Hyponatremia 8Health News:FDA Approves SAMSCA(TM) (tolvaptan), the First and Only Oral Vasopressin Antagonist to Treat Patients With Clinically Significant Hypervolemic and Euvolemic Hyponatremia 9Health News:Blue Cross and Blue Shield of Georgia and Piedmont Healthcare Announce Contract Renewal 2Health News:Thousands of Canada's best minds converge at Congress 2009 2Health News:Beazley's New Management Liability Coverage is Tailored to Unique Needs of Healthcare Organizations 2Health News:Beazley's New Management Liability Coverage is Tailored to Unique Needs of Healthcare Organizations 3Health News:Study: Lower Legal Drinking Age Increases Poor Birth Outcomes 2Health News:Study: Lower Legal Drinking Age Increases Poor Birth Outcomes 3
Breaking Medicine Technology:FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology 2FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology 3FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology 4Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 2Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 3Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 4Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 5Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 6Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 7Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 8Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 9Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 10Childrens Hospitals and Clinics of Minnesota Receives National Recognition for Quality and Efficiency 62578 1Childrens Hospitals and Clinics of Minnesota Receives National Recognition for Quality and Efficiency 62578 2Settlement in AMA Lawsuit against UnitedHealth Gets Preliminary Approval from Federal Court 62575 1Settlement in AMA Lawsuit against UnitedHealth Gets Preliminary Approval from Federal Court 62575 2VIDEO from Medialink and the American Nurses Association 28ANA 29 3A American Nurses Association Urges All Americans to Take Part in Health Care Refo 62572 1VIDEO from Medialink and the American Nurses Association 28ANA 29 3A American Nurses Association Urges All Americans to Take Part in Health Care Refo 62572 2